These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30052822)

  • 1. Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy.
    Penttilä T; Lehto M; Niiranen J; Mehtälä J; Khanfir H; Lassila R; Raatikainen P
    Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):29-36. PubMed ID: 30052822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF Registry.
    Raatikainen MJP; Penttilä T; Korhonen P; Mehtälä J; Lassila R; Lehto M
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):211-219. PubMed ID: 29514184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
    Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
    Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry.
    Lehto M; Niiranen J; Korhonen P; Mehtälä J; Khanfir H; Hoti F; Lassila R; Raatikainen P
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):657-665. PubMed ID: 28317274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation.
    Tan J; Bae S; Segal JB; Zhu J; Alexander GC; Segev DL; McAdams-DeMarco M
    Nephrology (Carlton); 2019 Feb; 24(2):234-244. PubMed ID: 29219209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
    Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin persistence among atrial fibrillation patients - why is treatment ended?
    Björck F; Ek A; Johansson L; Själander A
    Cardiovasc Ther; 2016 Dec; 34(6):468-474. PubMed ID: 27565120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
    Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
    Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation.
    Genovesi S; Rossi E; Gallieni M; Stella A; Badiali F; Conte F; Pasquali S; Bertoli S; Ondei P; Bonforte G; Pozzi C; Rebora P; Valsecchi MG; Santoro A
    Nephrol Dial Transplant; 2015 Mar; 30(3):491-8. PubMed ID: 25352571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA
    Denas G; Zoppellaro G; Padayattil Jose S; Antonucci E; Marongiu F; Poli D; Testa S; Tripodi A; Palareti G; Pengo V
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation.
    Chan YH; Chuang C; Chan CC; Lee HF; Huang YC; Huang YT; Chang SH; Wang CL; Chao TF; Kuo CT; Yeh YH; Chen SA
    Cardiovasc Diabetol; 2020 Mar; 19(1):30. PubMed ID: 32156277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.
    Gallagher AM; Setakis E; Plumb JM; Clemens A; van Staa TP
    Thromb Haemost; 2011 Nov; 106(5):968-77. PubMed ID: 21901239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of warfarin in elderly patients with non-valvular atrial fibrillation -- subanalysis of the J-RHYTHM Registry.
    Kodani E; Atarashi H; Inoue H; Okumura K; Yamashita T; Origasa H;
    Circ J; 2015; 79(11):2345-52. PubMed ID: 26329097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.
    An J; Niu F; Lang DT; Jazdzewski KP; Le PT; Rashid N; Meissner B; Mendes R; Dills DG; Aranda G; Bruno A
    J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26187996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin.
    Senoo K; Lip GY
    Stroke; 2016 Jun; 47(6):1665-8. PubMed ID: 27125527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ?
    Lehtola H; Hartikainen J; Hartikainen P; Kiviniemi T; Nuotio I; Palomäki A; Ylitalo A; Airaksinen KEJ; Mustonen P
    Clin Cardiol; 2018 May; 41(5):608-614. PubMed ID: 29745996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.